株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

中国のアトルバスタチン市場

Investigation Report on Chinese Atorvastatin Market, 2018-2022

発行 China Research and Intelligence 商品コード 674758
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.74円で換算しております。
Back to Top
中国のアトルバスタチン市場 Investigation Report on Chinese Atorvastatin Market, 2018-2022
出版日: 2018年08月01日 ページ情報: 英文 30 Pages
概要

当レポートでは、中国のアトルバスタチン市場について調査分析し、発展環境、売上、価格、主要メーカー、市場シェア、見通しについて、体系的な情報を提供しています。

第1章 アトルバスタチンの関連概念

  • 適応
  • 開発の歴史
  • 特許と政府の承認

第2章 中国のアトルバスタチンの売上

  • 売上高
  • 売上数量
  • 売上高:剤形別

第3章 中国のアトルバスタチン主要メーカーの分析

  • 市場シェア分析
  • Pfizer
  • Beijing Jialin Pharmaceutical Co., Ltd.
  • China Meheco Topfond Pharma Co., Ltd.
  • Zhejiang Neo-Dankong Pharmaceutical Co., Ltd.
  • Guangdong Baike Pharmaceutical Co., Ltd.

第4章 中国のさまざまなメーカーのアトルバスタチンの価格

  • Pfizer (商品名:Lipitor)
  • Beijing Jialin Pharmaceutical Co., Ltd. (商品名:Ale)
  • China Meheco Topfond Pharma Co., Ltd. (商品名:Youjia)
  • Zhejiang Neo-Dankong Pharmaceutical Co., Ltd. (商品名:Youliping)
  • Guangdong Baike Pharmaceutical Co., Ltd. (商品名:Jingshu)

第5章 中国のアトルバスタチン市場の見通し

  • 発展影響要因
  • 市場規模の予測
  • 市場動向の予測
目次
Product Code: 1808321

Description

The number of patients with hyperlipidemia is increasing in China with the life style change resulting from economic development and the rise of residents' income. It is estimated that there are over 100 million patients with hyperlipidemia and 160 million patients with dyslipidemia in China. And the figures are increasing every year.

Atorvastatin is a common drug that lowers blood cholesterol levels. It was developed by Pfizer in the trade name of Lipitor. It has been proved that Atorvastatin is safe and can decrease major cardiovascular events for patients with coronary heart disease, ischemic stroke, diabetes and high-risk patients with cardiovascular diseases such as hypertension. By the end of 2017, the global sales of Lipitor had exceeded USD 150 billion, creating a miracle in global drug sales.

According to CRI, Atorvastatin has been growing rapidly since it entered China, with its sales revenue increasing from less than CNY 200 million in 2005 to more than CNY 2.21 billion in 2017. There is a high demand for Atorvastatin in China. In addition to Pfizer's brand-name drug Lipitor, generic drugs of Beijing Jialin Pharmaceutical Co., Ltd., China Meheco Topfond Pharma Co., Ltd., Zhejiang Neo-Dankong Pharmaceutical Co., Ltd., Guangdong Baike Pharmaceutical Co., Ltd., etc. are also sold on the market. Pfizer captured the largest market share by sales value. Its market share exceeded 70% with a sales value over CNY 1.6 billion in 2017.

It is estimated that the number of patients with hyperlipidemia will continue to grow in China in the next few years, which will lead to a rising demand for Atorvastatin.

Topics Covered:

  • Development environment of Atorvastatin in China
  • Sales of Atorvastatin in China
  • Prices of Atorvastatin in China
  • Major Atorvastatin manufacturers in China
  • Market share of Atorvastatin by dosage form in China
  • Prospect of Chinese Atorvastatin Market, 2018-2022

Table of Contents

1 Relevant Concepts of Atorvastatin

  • 1.1 Indications for Atorvastatin
  • 1.2 Development History of Atorvastatin in China
  • 1.3 Patents and Government Approval on Atorvastatin in China

2 Sales of Atorvastatin in China, 2013-2017

  • 2.1 Sales Value of Atorvastatin
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value in Parts of China
  • 2.2 Sales Volume of Atorvastatin
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Atorvastatin by Dosage Form in China, 2013-2017
    • 2.3.1 Tablets
    • 2.3.2 Capsules

3 Analysis on Major Atorvastatin Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Atorvastatin Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Pfizer
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Pfizer's Atorvastatin in China
  • 3.3 Beijing Jialin Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Beijing Jialin Pharmaceutical Co., Ltd.'s Atorvastatin in China
  • 3.4 China Meheco Topfond Pharma Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of China Meheco Topfond Pharma Co., Ltd.'s Atorvastatin in China
  • 3.5 Zhejiang Neo-Dankong Pharmaceutical Co., Ltd.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Zhejiang Neo-Dankong Pharmaceutical Co., Ltd.'s Atorvastatin in China
  • 3.6 Guangdong Baike Pharmaceutical Co., Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Guangdong Baike Pharmaceutical Co., Ltd.'s Atorvastatin in China

4 Prices of Different Manufacturers' Atorvastatin in China, 2017-2018

  • 4.1 Pfizer (Trade Name: Lipitor)
  • 4.2 Beijing Jialin Pharmaceutical Co., Ltd. (Trade Name: Ale)
  • 4.3 China Meheco Topfond Pharma Co., Ltd. (Trade Name: Youjia)
  • 4.4 Zhejiang Neo-Dankong Pharmaceutical Co., Ltd. (Trade Name: Youliping)
  • 4.5 Guangdong Baike Pharmaceutical Co., Ltd. (Trade Name: Jingshu)

5 Prospect of Chinese Atorvastatin Market, 2018-2022

  • 5.1 Factors Influencing Development
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Government Approval of Atorvastatin in China
  • Chart Sales Value of Atorvastatin in China, 2013-2017
  • Chart Sales Value of Atorvastatin in Parts of China, 2013-2017
  • Chart Sales Volume of Atorvastatin in China, 2013-2017
  • Chart Market Share of Top 5 Atorvastatin Manufacturers by Sales Value, 2013-2017
  • Chart Sales Value and Market Share of Pfizer's Atorvastatin in China, 2013-2017
  • Chart Sales Value and Market Share of Beijing Jialin Pharmaceutical Co., Ltd.'s Atorvastatin in China, 2013-2017
  • Chart Sales Value and Market Share of China Meheco Topfond Pharma Co., Ltd.'s Atorvastatin in China, 2013-2017
  • Chart Sales Value and Market Share of Atorvastatin Tablets in China, 2013-2017
  • Chart Sales Value and Market Share of Atorvastatin Capsules in China, 2013-2017
  • Chart Prices of Beijing Jialin Pharmaceutical Co., Ltd.'s Atorvastatin in Parts of China, 2017-2018
  • Chart Prices of China Meheco Topfond Pharma Co., Ltd.'s Atorvastatin in Parts of China, 2017-2018
  • Chart Forecast on Sales Volume of Atorvastatin in China, 2018-2022
Back to Top